{"entity":{"id":"capillary-leak-syndrome-on-anticancer-drugs","kind":"protocol","name":"Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment","aka":["capillary leak syndrome","CLS","vascular leak syndrome","systemic capillary leak","tagraxofusp capillary leak","Elzonris albumin monitoring","dinutuximab capillary leak","interleukin-2 capillary leak"],"tldr":"A few cancer medicines can make the smallest blood vessels leaky, so fluid and protein seep out of the blood into the tissues. The signs are weight gain, swelling, breathlessness and low blood pressure. Teams watch weight, blood pressure and, for some of these medicines, a blood protein called albumin. If signs appear they pause the medicine and treat by that medicine's own rules.","summary":"Capillary leak syndrome (CLS) is loss of protein-rich fluid from the circulation: hypoalbuminaemia, oedema and weight gain, hypotension, and in severe cases pulmonary oedema, shock and acute kidney injury. Among anticancer drugs with records here, tagraxofusp and aldesleukin carry boxed warnings for it, dinutuximab and dinutuximab beta list it as a warning, and gemcitabine's label tells prescribers to stop the drug for good.\n\nThe tagraxofusp label has the most detailed rules. Albumin must be at least 3.2 g/dL before the first dose; cycle 1 is given in hospital; vital signs, albumin, transaminases and creatinine are checked before every dose. During dosing, an albumin below 3.5 g/dL or a fall of 0.5 g/dL or more from the start of the cycle, or a weight gain of 1.5 kg or more over the previous day's pre-dose weight, means the dose is held and 25 g of intravenous albumin is given every 12 hours or more often; oedema, fluid overload or hypotension add methylprednisolone 1 mg/kg a day and active fluid and blood pressure management. The label reports CLS in 53% of 122 patients by a broad definition, a median onset of 4 days, and four deaths.\n\nDinutuximab (children with high-risk neuroblastoma) needs 10 mL/kg of 0.9% saline over an hour before each infusion, close blood pressure monitoring, interruption for moderate to severe CLS with restart at half rate, and permanent discontinuation if life-threatening CLS recurs. The EU label for dinutuximab beta says the leak usually develops within hours of starting treatment, with low blood pressure and a fast pulse reported after 2 to 12 hours, and stops the drug for good for recurrent or grade 4 CLS. Aldesleukin is given only in a hospital with an intensive care facility and is withheld when organ perfusion fails.\n\nThe sources pull in different directions on fluids: the dinutuximab label requires pre-hydration and the tagraxofusp label uses intravenous fluids for hypotension, while the review of anticancer drug-induced CLS says saline should be limited because it worsens oedema. None of the sources read cites a randomised trial of albumin, steroids or any fluid strategy for drug-induced CLS. The reader's own team's protocol comes first.","asOf":"2026-11-17","links":[],"tags":[],"related":["gemcitabine","differentiation-syndrome-recognition-and-treatment","fluid-retention-and-effusions-on-kinase-inhibitors","crs-grading-and-management","febrile-neutropenia-first-hour"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tagraxofusp","dinutuximab","aldesleukin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"simple":"Some cancer medicines can make fluid leak out of your blood vessels. You may gain weight, swell up, feel breathless or feel faint. Your team checks you closely around each dose so they can pause the medicine and treat the leak. Tell them straight away about new swelling, breathlessness or feeling faint, and report weight gain too.","domain":"emergencies","setting":{"who":["nurse","doctor","pharmacist","patient-or-carer"],"where":["ward","chemotherapy-day-unit","intensive-care","home","telephone-triage"]},"population":"Adults and children from 2 years having tagraxofusp for blastic plasmacytoid dendritic cell neoplasm; children having dinutuximab (US label: paediatric patients with high-risk neuroblastoma) or dinutuximab beta (EU label: from 12 months); adults having aldesleukin (interleukin-2) for metastatic kidney cancer or melanoma, the uses in the US label; and anyone having gemcitabine. The tagraxofusp, aldesleukin and gemcitabine steps are adult practice unless stated; the dinutuximab steps are paediatric and are carried out in children's cancer units under their own protocols. Capillary leak as part of cytokine release syndrome after CAR-T or bispecific antibodies, of differentiation syndrome, or of engraftment after a transplant is covered by those protocols and not here.","trigger":"Before each dose of one of these medicines, and whenever a person on one has new weight gain, swelling, breathlessness, low blood pressure, a falling albumin or a falling urine output.","steps":[{"action":"Before the first dose of tagraxofusp, confirm serum albumin is at least 3.2 g/dL and that heart function is adequate","why":"The label makes both a condition of starting, and warns that capillary leak on tagraxofusp can be life-threatening or fatal.","source":"label-tagraxofusp","quote":"Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL."},{"action":"Give the first cycle of tagraxofusp in hospital and observe for at least 24 hours after the last infusion","why":"In the label's trial data all but 5 of the 65 patients with capillary leak had it in the first cycle, at a median of 4 days.","source":"label-tagraxofusp","quote":"Administer Cycle 1 of ELZONRIS in the inpatient setting with patient observation through at least 24 hours after the last infusion."},{"action":"Before preparing every dose of tagraxofusp, check vital signs, albumin, liver enzymes and creatinine","why":"The label's rules for holding a dose and treating capillary leak depend on these results, so they are seen before the dose is made up.","source":"label-tagraxofusp","quote":"Monitor vital signs and check albumin, transaminases, and creatinine prior to preparing each dose of ELZONRIS."},{"action":"Weigh the patient before each dose, compare with the previous day's pre-dose weight, and advise them to weigh themselves daily","why":"On tagraxofusp the label acts on a pre-dose weight 1.5 kg or more above the previous day's pre-dose weight, and it lists weight gain among the signs of leak.","source":"label-tagraxofusp","quote":"Advise patients to weigh themselves daily"},{"action":"On tagraxofusp, if albumin is below 3.5 g/dL or has fallen by 0.5 g/dL or more since the start of the cycle, hold the dose and give 25 g of intravenous albumin every 12 hours (or more often as practical) until albumin is at least 3.5 g/dL and no more than 0.5 g/dL below its value at the start of the cycle","why":"The label treats a falling albumin as a sign of capillary leak and interrupts dosing until it has resolved.","source":"label-tagraxofusp","quote":"Administer 25g intravenous albumin (q12h or more frequently as practical) until serum albumin is ≥ 3.5 g/dL AND not more than 0.5 g/dL lower than the value measured prior to dosing initiation of the current cycle."},{"action":"On tagraxofusp, if pre-dose weight is up by 1.5 kg or more on the previous day, hold the dose, give 25 g of intravenous albumin every 12 hours (or more often as practical), and manage fluid by blood pressure: fluids and vasopressors if low, diuretics if normal or high","why":"The label matches the fluid treatment to the blood pressure and continues until the weight gain has resolved.","source":"label-tagraxofusp","quote":"manage fluid status as indicated clinically (e.g., generally with intravenous fluids and vasopressors if hypotensive and with diuretics if normotensive or hypertensive)"},{"action":"On tagraxofusp, for oedema, fluid overload or low blood pressure, hold the dose, give albumin until it is at least 3.5 g/dL, add methylprednisolone 1 mg/kg a day (or an equivalent steroid) until the sign resolves or as clinically indicated, and manage fluid and blood pressure actively","why":"This is the label's rule once the leak is causing these signs. The label does not give a reason for the steroid.","source":"label-tagraxofusp","quote":"Administer 1 mg/kg of methylprednisolone (or an equivalent) per day, until resolution of CLS sign/symptom or as indicated clinically."},{"action":"Restart tagraxofusp in the same cycle only if every sign has resolved and no treatment for unstable blood pressure was needed; otherwise hold it for the rest of the cycle","why":"The label allows the next cycle only once every sign has resolved and the blood pressure is stable.","source":"label-tagraxofusp","quote":"ELZONRIS administration should be held for the remainder of the cycle if CLS signs/symptoms have not resolved or the patient required measures to treat hemodynamic instability"},{"action":"Before each dinutuximab infusion (children), give 0.9% sodium chloride 10 mL/kg intravenously over 1 hour","why":"The label requires this hydration before every infusion, under its warnings on capillary leak and low blood pressure.","source":"label-dinutuximab","quote":"Administer 0.9% Sodium Chloride Injection, USP 10 mL/kg as an intravenous infusion over 1 hour just prior to initiating each Unituxin infusion."},{"action":"During dinutuximab, monitor blood pressure closely and interrupt the infusion for symptomatic or severe capillary leak; restart at half the rate after moderate or severe leak, and stop for good if life-threatening leak recurs","why":"Severe capillary leak happened in 31 patients (23%) given dinutuximab in the registration trial, and the label manages it by interrupting, slowing or stopping the infusion.","source":"label-dinutuximab","quote":"Immediately interrupt or discontinue Unituxin and institute supportive management in patients with symptomatic or severe capillary leak syndrome"},{"action":"During dinutuximab beta (EU product), watch circulation and breathing closely from the first hours; interrupt for capillary leak, give supportive measures, resume at half rate once it resolves or improves to grade 1 to 2, and stop for good if it recurs or reaches grade 4","why":"The EU label says the leak usually develops within hours of starting treatment, and that low blood pressure and a fast pulse are reported after 2 to 12 hours.","source":"smpc-qarziba","quote":"Careful monitoring of circulatory and respiratory function is required."},{"action":"Give aldesleukin only in a hospital with an intensive care facility, and monitor vital signs, weight, fluid intake, albumin and urine output","why":"The label says capillary leak may begin immediately after aldesleukin is started and can damage the heart, lungs, kidneys and liver.","source":"label-aldesleukin","quote":"Monitor for signs and symptoms of CLS including assessments of vital signs, weight, fluid intake, albumin levels and urine output."},{"action":"Withhold or stop aldesleukin if organs are not being perfused: confusion, falling urine output, oxygen saturation below 90%, systolic blood pressure below 90 mmHg or a new arrhythmia","why":"The label lists these as the signs that organs are no longer being supplied with enough blood.","source":"label-aldesleukin","quote":"Withhold or discontinue Proleukin for failure to maintain organ perfusion as demonstrated by altered mental status, reduced urine output, oxygen saturation <90%, a fall in the systolic blood pressure below 90 mm Hg, or onset of cardiac arrhythmias."},{"action":"If capillary leak develops on gemcitabine, stop gemcitabine permanently","why":"The label reports severe consequences and gives no rule for restarting.","source":"label-gemcitabine","quote":"Permanently discontinue Gemcitabine for Injection if CLS develops during therapy."},{"action":"On tagraxofusp, when capillary leak is suspected, also assess for infection or sepsis and for heart or lung events","why":"The consensus paper lists these checks among its precautions for tagraxofusp. It gives no reason, and they are in its discussion, not one of its listed recommendations.","source":"pagano-2023","quote":"in addition to other standard practices evaluating for infection/sepsis, other cardiac/pulmonary events during the suspected time of CLS","grade":"Consensus position paper, discussion text; not graded"},{"action":"Limit saline infusions given to restore the circulating volume","why":"The review says saline may worsen the swelling of the surrounding tissues and may damage limb muscles and nerves. The labels above use fluids differently; see the variants.","source":"izzedine-2022","quote":"As in idiopathic CLS, administration of saline infusions to restore intravascular volume should be limited as it may worsen the edema of the surrounding tissues and potentially cause damage to limb muscles and nerves."},{"action":"On tagraxofusp, advise the patient to contact the team about new or worsening swelling, weight gain, breathlessness or low blood pressure after an infusion","why":"The label says capillary leak may be life-threatening or fatal if it is not properly managed. It does not say how quickly to call.","source":"label-tagraxofusp","quote":"to contact their health care professional for signs and symptoms associated with CLS including new or worsening edema, weight gain, shortness of breath, and/or hypotension after infusion."},{"action":"On aldesleukin, advise the patient to tell the team immediately about new or worsening low blood pressure, breathlessness or swelling","why":"The aldesleukin label asks for an immediate report. The dinutuximab label likewise tells patients and caregivers to report any signs or symptoms immediately.","source":"label-aldesleukin","quote":"Advise patients about the risk of capillary leak syndrome and to inform their healthcare provider immediately if they develop new or worsening symptoms of hypotension, dyspnea, or edema"}],"bestInClass":{"statement":"For tagraxofusp, the label's own scheme is the most specific rule among the sources read, and the consensus paper on blastic plasmacytoid dendritic cell neoplasm lists the same kinds of precaution without thresholds or doses. The label's scheme: albumin of at least 3.2 g/dL before the first dose, cycle 1 in hospital, albumin, weight and vital signs before every dose, the dose held and 25 g of intravenous albumin given every 12 hours or more often when albumin falls below 3.5 g/dL (or by 0.5 g/dL or more from the start of the cycle) or weight rises 1.5 kg or more in a day, methylprednisolone 1 mg/kg a day for oedema, fluid overload or hypotension, and no further doses that cycle after haemodynamic instability. For the other drugs the labels give stopping rules and little else: dinutuximab with pre-hydration, interruption and restart at half rate; dinutuximab beta stopped for recurrent or grade 4 leak; aldesleukin withheld for failed organ perfusion; gemcitabine stopped for good. On fluids the sources differ and both views are shown: pre-hydration and fluids for hypotension in the dinutuximab and tagraxofusp labels, against the reviewers' advice to limit saline because it worsens oedema. None of the sources read cites a comparative trial.","sources":["label-tagraxofusp","pagano-2023","label-dinutuximab","smpc-qarziba","label-aldesleukin","label-gemcitabine","izzedine-2022"]},"variants":[{"name":"Fluids: pre-hydrate and resuscitate, or restrict","differs":"The dinutuximab label requires 10 mL/kg of saline before every infusion and the tagraxofusp label uses intravenous fluids and vasopressors for hypotension. The review of anticancer drug-induced capillary leak says saline to restore volume should be limited, notes that albumin's effect is blunted because it leaks too, and that starch solutions have been linked to more deaths and kidney injury in the critically ill.","evidence":"The sources read cite no comparative data. The review states: there is a lack of evidence to guide the choice of fluid therapy.","sources":["label-dinutuximab","label-tagraxofusp","izzedine-2022"]},{"name":"Dinutuximab (US) and dinutuximab beta (EU) rules","differs":"The US label interrupts dinutuximab for moderate to severe leak and resumes at 50% of the previous rate; for life-threatening leak it stops for the cycle, gives later cycles at 50% rate, and stops for good on first recurrence. The EU label for dinutuximab beta interrupts, resumes at 50% rate once the reaction resolves or improves to grade 1 to 2, and stops for good for recurrent or grade 4 leak (needing a ventilator).","evidence":"Label rules. Severe (grade 3 to 5) leak occurred in 31 of the children (23%) given dinutuximab in the registration trial; the EU label says that overall 5.2% of capillary leak was severe (grade 3 to 4) and that its frequency fell over the treatment courses, and it lists capillary leak at 35% across investigator-sponsored studies. The two products, their schedules and the drugs given with them differ, so the figures are not a comparison.","sources":["label-dinutuximab","smpc-qarziba"]},{"name":"Diuretic choice and second-line drugs","differs":"The review suggests amiloride as the diuretic because it lowers blood pressure less, and lists steroids, aminophylline, theophylline or terbutaline, thalidomide, antihistamines, plasmapheresis and intravenous immunoglobulin as agents tried in secondary capillary leak. The tagraxofusp label names diuretics only as a class and steroids as methylprednisolone.","evidence":"The review says these agents have been tried sporadically with varying effect, and cites case reports. It states that intravenous immunoglobulin, which may help in the idiopathic form, has no documented efficacy in forms caused by anticancer drugs.","sources":["izzedine-2022","label-tagraxofusp"]},{"name":"Manufacturer-funded guidance on tagraxofusp","differs":"A 2025 paper by eleven authors, one of them affiliated with the Menarini Group, funded by the Menarini Group (which markets tagraxofusp), discusses patient selection, monitoring and early intervention in practice. Only its abstract was read.","evidence":"The abstract quotes capillary leak in 21% of patients at 12 micrograms/kg a day in the registration trial, mostly grade 2, with two deaths, and says that with strict monitoring it is typically mild and mostly in cycle 1. No recommendation here rests on it.","sources":["lane-2025"]}],"grades":[{"claim":"Tagraxofusp: monitor albumin before each dose and assess for weight gain, oedema, pulmonary oedema and hypotension","grade":"Regulatory label; not graded","source":"label-tagraxofusp","quote":"During treatment with ELZONRIS, monitor serum albumin levels prior to the initiation of each dose of ELZONRIS and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability"},{"claim":"Tagraxofusp: capillary leak in 53% of 122 patients by the label's definition, median onset 4 days, four deaths","grade":"Regulatory label; not graded","source":"label-tagraxofusp","quote":"The median time to onset was 4 days (range - 1 to 46 days), and all but 5 patients experienced an event in Cycle 1."},{"claim":"Tagraxofusp: the label's definition of capillary leak","grade":"Regulatory label; not graded","source":"label-tagraxofusp","quote":"hypoalbuminemia (including albumin value less than 3.0 g/dL), edema (including weight increase of 5 kg or more), hypotension (including systolic blood pressure less than 90 mmHg)."},{"claim":"Tagraxofusp: precautions as the consensus paper lists them in its discussion","grade":"Consensus position paper, discussion text; not graded","source":"pagano-2023","quote":"monitoring and replacing of albumin, measurement of daily weights, albumin levels, vital signs (Body Temperature, Pulse Rate, Respiration Rate, Blood Pressure) during infusion days; hospitalization during cycle 1 for optimal administration; and appropriate use of diuretics when indicated, and employment of measures such as high-dose steroids for active treatment"},{"claim":"Dinutuximab: severe capillary leak in 31 patients (23%) in the registration trial","grade":"Regulatory label; not graded","source":"label-dinutuximab","quote":"In Study 1, severe (Grade 3 to 5) capillary leak syndrome occurred in 31 (23%) patients in the Unituxin/RA group and in no patients treated with RA alone."},{"claim":"Dinutuximab beta: stop permanently for recurrent or grade 4 capillary leak","grade":"Regulatory label; not graded","source":"smpc-qarziba","quote":"recurrent or grade 4 capillary leak syndrome (requires ventilator support)"},{"claim":"Dinutuximab beta: timing of clinical signs","grade":"Regulatory label; not graded","source":"smpc-qarziba","quote":"CLS usually develops within hours after initiation of treatment, while clinical symptoms (i.e. hypotension, tachycardia) are reported to occur after 2 to 12 hours."},{"claim":"Aldesleukin: give in a hospital with intensive care","grade":"Regulatory label; not graded","source":"label-aldesleukin","quote":"Administer Proleukin in a hospital setting with an intensive care facility."},{"claim":"No specific treatment exists for anticancer drug-induced capillary leak","grade":"Narrative review; not graded","source":"izzedine-2022","quote":"There is no specific treatment of this drug side effect."},{"claim":"Evidence on fluid choice is lacking","grade":"Narrative review; not graded","source":"izzedine-2022","quote":"There is a lack of evidence to guide the choice of fluid therapy."}],"sources":[{"key":"label-tagraxofusp","label":"Elzonris (tagraxofusp) injection: US prescribing information, boxed warning, section 2 (Tables 1 and 2) and section 5.1","publisher":"Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine)","year":2024,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80eb1080-fe20-4af0-b2a5-a67999923fa8","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-dinutuximab","label":"Unituxin (dinutuximab) injection: US prescribing information, sections 2.2, 2.3, 5.3 and 5.4","publisher":"United Therapeutics (DailyMed, US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d66bdf0d-9d65-45de-ae5b-a58617c27492","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"smpc-qarziba","label":"Qarziba (dinutuximab beta): EU product information (first authorised 8 May 2017; text last updated 29 October 2026), summary of product characteristics sections 4.2, 4.4 and 4.8","publisher":"European Medicines Agency (marketing authorisation holder Recordati Netherlands B.V.)","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-aldesleukin","label":"Proleukin (aldesleukin) injection: US prescribing information, boxed warning and section 5.1","publisher":"Iovance Biotherapeutics (DailyMed, US National Library of Medicine)","year":2024,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3c516ad-d405-4fbe-af6a-962080dbfa7d","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-gemcitabine","label":"Gemcitabine for injection: US prescribing information, section 5.9","publisher":"Sagent Pharmaceuticals (DailyMed, US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44bcc16c-341d-49e8-a1c6-95d084667aca","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"izzedine-2022","label":"Anticancer drug-induced capillary leak syndrome","publisher":"Kidney International Reports (Izzedine et al.)","year":2022,"url":"https://doi.org/10.1016/j.ekir.2022.02.014","doi":"10.1016/j.ekir.2022.02.014","gradingScheme":"Narrative review; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"pagano-2023","label":"Unmet clinical needs and management recommendations for blastic plasmacytoid dendritic cell neoplasm: a consensus-based position paper from an ad hoc international expert panel","publisher":"HemaSphere (Pagano et al.; no funding statement printed; several panel members declare roles with Stemline or Menarini, which market tagraxofusp)","year":2023,"url":"https://doi.org/10.1097/HS9.0000000000000841","doi":"10.1097/HS9.0000000000000841","gradingScheme":"Expert panel consensus by a Delphi process; statements are not graded. The capillary leak precautions are in the discussion text, not a listed recommendation.","read":"full-text","accessed":"2026-11-17"},{"key":"lane-2025","label":"Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (funded by the Menarini Group)","publisher":"Leukemia & Lymphoma (Lane et al.; funder the Menarini Group, one author a Menarini Group employee)","year":2025,"url":"https://doi.org/10.1080/10428194.2025.2557505","doi":"10.1080/10428194.2025.2557505","read":"abstract","accessed":"2026-11-17"}],"upgrades":[],"gaps":["None of the sources read cites a randomised trial of albumin replacement, steroids, diuretics or any fluid strategy for capillary leak caused by an anticancer drug. The tagraxofusp scheme is a label rule, its safety data come from a single-arm trial, and the review read states that there is no specific treatment.","The sources differ on fluids: pre-hydration and fluids for hypotension in the dinutuximab and tagraxofusp labels, limited saline in the review. No source read says how to reconcile them in one patient.","The tagraxofusp label reports capillary leak in 53% of 122 patients by a broad definition; the consensus paper (citing the trial's three-year update) and the abstract of a manufacturer-funded paper quote 21% from the registration trial. The definitions differ and no source read sets them side by side.","Lane et al., Leuk Lymphoma 2025 (funded by the Menarini Group), the most recent paper on managing tagraxofusp capillary leak, is not open access and was read as an abstract only. The earlier management papers by the trial investigators were not found in open full text.","The dinutuximab and dinutuximab beta labels do not say what 'supportive management' of capillary leak consists of in a child (albumin, diuretics, steroids, vasopressors). Paediatric oncology group guidance was not read, and the dinutuximab beta dose table could be quoted only in part because of its column layout.","The aldesleukin label says to start 'standard management for CLS, which may include intensive care' without defining it, and no current guideline on high-dose interleukin-2 toxicity was read.","Gemcitabine: the label says only to stop the drug. The review says patients typically respond to systemic steroids and that the incidence is unknown.","Other anticancer drugs reported to cause capillary leak (the review names clofarabine, bortezomib, rituximab, alemtuzumab and checkpoint inhibitors, among others) are not covered because no label rule for capillary leak was read for them. Moxetumomab pasudotox has label rules but is recorded here as withdrawn; its label was read on 16 November 2026 and was not re-read on 17 November 2026.","The tagraxofusp label tells patients to contact their health care professional about signs of capillary leak but sets no time limit; the aldesleukin and dinutuximab labels and the Qarziba package leaflet say immediately. No source read gives a patient a single symptom list and time limit across all of these medicines.","On 17 November 2026 the EMA page for Qarziba showed its product information last updated on 29 October 2026; the text read is that current version. The printed date of revision in the PDF is a blank template field.","The US label for aldesleukin does not use the words high dose; this page describes the label's own regimen and says nothing about lower-dose or subcutaneous interleukin-2.","No glossary term for capillary leak syndrome exists in the corpus to link."]},"route":"/protocols/capillary-leak-syndrome-on-anticancer-drugs/","neighbours":{"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/"}],"protocol":[{"id":"crs-grading-and-management","kind":"protocol","name":"Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids","route":"/protocols/crs-grading-and-management/"},{"id":"differentiation-syndrome-recognition-and-treatment","kind":"protocol","name":"Differentiation syndrome on IDH, FLT3 and menin inhibitors and on tretinoin or arsenic trioxide: recognition and treatment","route":"/protocols/differentiation-syndrome-recognition-and-treatment/"},{"id":"fluid-retention-and-effusions-on-kinase-inhibitors","kind":"protocol","name":"Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs","route":"/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/"},{"id":"low-potassium-and-low-phosphate-on-anticancer-drugs","kind":"protocol","name":"Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds","route":"/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/"},{"id":"febrile-neutropenia-first-hour","kind":"protocol","name":"Suspected febrile neutropenia (neutropenic sepsis): the first hour","route":"/protocols/febrile-neutropenia-first-hour/"}]}}